DBV Technologies

Scientists Have Developed a Patch That Could Stop Severe Peanut Allergies

It just passed a phase II clinical trial.

LYDIA RAMSEY, BUSINESS INSIDER
6 MAR 2017
 

A treatment for one of the most common food allergies out there just got even more data that it's working. Roughly 1.5 million children in the US are allergic to peanuts, an allergy that can often be so severe that even the smallest amount of contact can set off an extreme reaction.

 

To counter that, DBV Technologies is working on a patch that works to lessen that severity.

In new phase two data presented at the American Academy of Allergy, Asthma and Immunology conference on Sunday, the company showed that 83 percent of children ages 6 to 11 who took part in the trial could eat 1,000 milligrams of peanuts without having an allergic reaction after wearing a patch for three years.

That's 10-times the amount of peanut that the participants could handle when they first joined the trial. Though the phase two data looked at people between the ages of 6 and 55, the best responses came from children on the trial.

Allergies are your immune system's response to a substance that may not be harmful to others. They're the sixth leading cause of chronic disease in the US.

According to the CDC, an estimated 4-6 percent of children in the US have food allergies, with peanuts being one of the worst offenders.

In December 2015, DBV kicked off a phase 3 trial that looks at how the patch works in kids aged 4-11, which along with this data will set the company up for the FDA approval process.

How the patch works

The immune-system-targeting drug is delivered through the skin through a process called epicutaneous immunotherapy.

 

Inside each patch is a sprayed-on sample of peanut protein. Once you put it on, the protein makes its way into your immune system through your skin.

Since it's delivered this way, the allergen never makes it to the blood stream, which would cause the allergic reaction you're trying to avoid.

Based on the data from DBV's phase two trial, those who used the patch for three years at the 250 microgram dose (the highest dose) had the best responses to the treatment.

The patch treatment is a departure from the way allergies are typically treated.

Typically, the only way to lessen an allergic reaction is through 'desensitisation', a process in which you gradually introduce small amounts of the allergen into your body. In the case of peanut allergies, that means eating the peanut outright.

The problem with this method is that it can be risky, since it can cause an allergic reaction that spreads throughout the body through the blood stream.

Other, more common methods, for treating allergies have been focused around treating the symptoms of the allergic reaction; i.e. using antihistamines like Benadryl or shots of epinephrine in extreme cases.

Beyond peanut allergies, DBV is developing patches to treat other food allergies such as milk and eggs - among the most common food allergies - and other non-food allergies that are connected to asthma.

The company's also exploring treatments for Crohn's disease, celiac disease, and type 1 diabetes that use the same immunotherapy technology.

This article was originally published by Business Insider.

More from Business Insider:

More From ScienceAlert

Here's what Juno discovered when it flew through Jupiter's Great Red Spot
7 hours ago
The world's e-waste is piling up at an alarming rate, says new report
6 hours ago